Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study-Reference-Cited by-同舟云学术

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

Published:2023-08 Issue: Volume:94 Page:104665
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Yu Hui Jing^ORCID,Dickson Samuel P.,Wang Pei-Ning,Chiu Ming-Jang,Huang Chin-Chang,Chang Chiung-Chih,Liu Hope,Hendrix Suzanne B.,Dodart Jean-Cosme,Verma Ajay,Wang Chang Yi,Cummings Jeffrey

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference25 articles.

1. 2021 Alzheimer's disease facts and figures;Alzheimers Dement,2021

2. Economic burden of Alzheimer disease and managed care considerations;Winston Wong;Am J Manag Care,2020

3. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics;Karran;Nat Rev Drug Discov,2022

4. Past, present and future of therapeutic strategies against amyloid-beta peptides in Alzheimer's disease: a systematic review;Jeremic;Ageing Res Rev,2021

5. Lecanemab in early Alzheimer's disease;van Dyck;N Engl J Med,2023

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential therapeutic natural compounds for the treatment of Alzheimer's disease;Phytomedicine;2024-09

2. Active Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease;Vaccines;2024-08-28

3. Alzheimer’s disease and immunotherapy;Current Medicine;2024-08-23

4. Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review;ACS Chemical Neuroscience;2024-08-22

5. A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer’s disease in 3xTg mice;npj Vaccines;2024-08-20